Logo image
Back
Renal metastasis to the pancreas: a comprehensive review
Journal article   Peer reviewed

Renal metastasis to the pancreas: a comprehensive review

Hassan Aziz, Aditya Kotla, Raegen Abbey, Brandon C Toliver, Matthew Gosse, Nikahat Yasmine, Yashant Aswani and Timothy Pawlik
Journal of gastrointestinal surgery, Vol.30(4), 102347
04/2026
DOI: 10.1016/j.gassur.2026.102347
PMID: 41617051

View Online

Abstract

Background Pancreatic metastases are rare, accounting for 2% to 5% of all pancreatic malignancies. Renal cell carcinoma (RCC) is the most common primary cancer that metastasizes to the pancreas and accounts for 30% to 40% of all pancreatic metastatic lesions. Most reported cases involve clear cell RCC (ccRCC), although data regarding pancreatic metastases from non–ccRCC subtypes remain limited. Unlike metastases from other primary tumors, pancreatic metastases from RCC (PM-RCC) often follow a more indolent clinical course and are associated with a relatively favorable prognosis, suggesting distinct underlying biological behavior. Methods A comprehensive literature review was conducted using the MEDLINE/PubMed, Google Scholar, Cochrane Library, and Web of Science databases (January 1993 to May 2025). Eligible studies included full-text articles, case reports, and original research describing RCC metastasis to the pancreas, with an emphasis on the mechanism, diagnosis, treatment, and outcomes. Results The disproportionate tendency of kidney cancer to metastasize to the pancreas is best explained by the “seed and soil” hypothesis, reflecting a selective affinity between RCC cells and the pancreatic microenvironment. PM-RCC are usually metachronous, often occurring many years after nephrectomy, and are frequently asymptomatic and discovered incidentally on surveillance imaging. Characteristic imaging findings include hypervascular lesions on contrast-enhanced computed tomography or magnetic resonance imaging. Histopathologic confirmation is crucial, as PM-RCC have a markedly better prognosis than primary pancreatic neoplasms. Surgical resection remains the mainstay of treatment of isolated disease, with a 5-year survival rate exceeding 50%. In the era of targeted immunotherapy, systemic treatments further improve outcomes, with the median overall survival surpassing that of patients with extrapancreatic metastases. Conclusion PM-RCC are a unique clinical and biological entity characterized by indolent progression, favorable survival, and a strong response to surgical and targeted therapies. Understanding the molecular and microenvironmental mechanisms underlying this selective organotropism may refine therapeutic strategies and provide insights into the broader principles of metastatic disease.
 Metastasis Pancreas Renal Imaging Outcomes

Details

Metrics

1 Record Views
Logo image